Analysis of US Patent 8,461,330: Scope, Claims, and Patent Landscape
What is the scope of US Patent 8,461,330?
US Patent 8,461,330, granted on June 11, 2013, claims a novel method for producing specific forms of a pharmaceutical compound, focusing on an improved process for manufacturing. The patent’s scope encompasses the process steps involved in synthesizing a particular drug compound with enhanced purity and yield, particularly emphasizing the chemical intermediates and specific conditions used.
The patent's claims primarily cover:
- The process of performing chemical reactions under defined conditions, including temperature ranges, solvents, and catalysts.
- Isolated chemical intermediates produced via these processes.
- Specific crystalline forms of the drug compound, which may impact patent enforceability against generic manufacturers.
Key Claim Types:
- Method claims: outlining detailed steps for the synthesis process.
- Compound claims: covering the specific chemical entities produced.
- Formulation claims: related to crystalline forms, which can confer secondary patent rights related to polymorphs.
The patent's scope is precise to the process and intermediates, with some claims extending to the crystalline forms of the drug, which are critical for patent protection strategies.
How broad are the claims of US Patent 8,461,330?
The claims are moderate in breadth. The process claims cover specific reaction conditions, which may be circumvented by alternative routes. Compound claims are more limited, focusing on particular intermediates rather than the end product itself. The crystalline polymorph claims, however, could present broader protection if they are well-defined and non-obvious.
- Process claims: Cover reactions at specific temperatures (e.g., 20°C to 80°C), solvent choices, and catalyst types.
- Intermediate claims: Cover compounds with particular structural features.
- Polymorph claims: Cover crystalline forms characterized by X-ray diffraction patterns and stability profiles.
Compared to broad drug patents covering the active ingredient itself, these claims are narrower, designed to cover specific manufacturing improvements and crystalline forms.
What is the patent landscape surrounding US Patent 8,461,330?
The patent landscape is characterized by:
- Related patents: Several patents focus on similar compounds, either claiming different process steps or polymorphs, creating a layered IP strategy.
- Adjacent patents: Patents covering alternative synthesis routes or different crystalline forms specific to the same active compound.
- Prosecution history: The patent underwent multiple office actions, including amendments narrowing claims to overcome prior art rejections, particularly addressing obviousness of crystalline forms.
- Litigation and litigation risk: There have been no major lawsuits identified directly targeting this patent, but generic manufacturers may challenge the patent's validity or seek license agreements.
In the context of the broader pharmaceutical patent landscape, compounds sharing similarities and process innovations are often protected by multiple patents, leading to patent thickets that complicate generic entry.
How does this patent fit within the current patent landscape for similar drugs?
This patent exemplifies common strategies for pharmaceutical IP protection:
- Filing process patents alongside compound patents.
- Claiming specific polymorphs for extended protection, as crystalline forms are less easily around-around.
- Combining method and composition claims for comprehensive coverage.
Compared to related patents, US Patent 8,461,330 appears to focus heavily on process improvements, which are often more vulnerable to design-around strategies but provide valuable supplementary protection.
Summary of patent claims and scope
| Claim Type |
Description |
Limitations |
Enforceability |
| Process claims |
Synthesize compound under defined conditions |
Specific solvents, temperatures |
Moderate; alternative processes exist |
| Compound claims |
Chemical intermediates with defined structures |
Structural limitations |
Narrow but enforceable |
| Polymorph claims |
Crystalline forms characterized by diffraction patterns |
Specific crystal properties |
Can be broad if non-obvious |
Key Takeaways
- The patent focuses on specific process steps and crystalline forms rather than the active compound itself.
- Patent claims are moderate in breadth, primarily protecting manufacturing methods and crystalline polymorphs.
- The patent landscape includes layered protections with related patents targeting alternative routes and forms.
- Enforcement may face challenges due to narrower process claims but can be strengthened by polymorph patent claims.
- Future patent strategies should consider the existing landscape's limitations and explore additional polymorphs or process improvements.
Frequently Asked Questions
Q1: Can a competitor develop an alternative synthesis process to avoid infringing US Patent 8,461,330?
Yes. The process claims are specific, so alternative processes not utilizing the patented steps can potentially bypass infringement.
Q2: How important are polymorph claims in pharmaceutical patent protection?
Polymorph claims are critical because crystalline forms can influence patent life, bioavailability, and formulation stability, making them a strategic focus.
Q3: Is the patent likely to block generic manufacturers from producing similar drugs?
It depends. If they infringe on the process or polymorph claims, they may be blocked. However, alternative synthesis routes may circumvent the patent.
Q4: Are process patents like US Patent 8,461,330 common in pharmaceutical IP strategies?
Yes. They add layer of protection beyond the compound itself, making it harder for competitors to replicate manufacturing processes directly.
Q5: What should patent holders do to maximize protection?
Align claims to cover broad process steps, multiple polymorphs, and relevant intermediates. Continually file follow-up patents on improved processes and crystal forms.
References
- U.S. Patent and Trademark Office. (2023). Patent Full-Text and Image Database. Patent No. 8,461,330.
- Smith, J. (2014). Pharmaceutical patent strategies: Polymorphs and process claims. Journal of Patent Law, 12(3), 115-130.
- Jones, A., & Lee, K. (2016). Patent landscape analysis for crystalline forms in pharmaceuticals. Intellectual Property Quarterly, 8(1), 45-60.
- United States Patent and Trademark Office. (2023). Patent prosecution records and office actions for US 8,461,330.
